» Articles » PMID: 37573441

Potential Immunosuppressive Clonal Hematopoietic Mutations in Tumor Infiltrating Immune Cells in Breast Invasive Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2023 Aug 12
PMID 37573441
Authors
Affiliations
Soon will be listed here.
Abstract

A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune cells. These mutations cannot "drive" tumor growth, however, they may "facilitate" it by inhibiting an effective anti-tumor immune response. To identify potential immunosuppressive clonal hematopoietic (CH) mutations in TII cells, we analyzed exome and RNA sequencing data from matched tumor and normal blood samples, and single-cell RNA sequencing data, from breast cancer patients. We selected mutations that were somatic, present in TII cells, clonally expanded, potentially pathogenic, expressed in TII cells, unlikely to be a passenger mutation, and in immune response associated genes. We identified eight potential immunosuppressive CH mutations in TII cells. This work is a first step towards determining if immunosuppressive CH mutations in TII cells can affect the progression of solid tumors. Subsequent experimental confirmation could represent a new paradigm in the etiology of cancer.

Citing Articles

Clonal Hematopoiesis in Women With Breast Cancer.

Mayerhofer C, Freedman R, Parsons H, Partridge A, Miller P J Clin Oncol. 2025; 43(7):861-867.

PMID: 39823557 PMC: 11867839. DOI: 10.1200/JCO-24-01848.


An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations.

Anandakrishnan R, Shahidi R, Dai A, Antony V, Zyvoloski I PLoS One. 2024; 19(8):e0307232.

PMID: 39172974 PMC: 11341013. DOI: 10.1371/journal.pone.0307232.

References
1.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

2.
Anandakrishnan R, Varghese R, Kinney N, Garner H . Estimating the number of genetic mutations (hits) required for carcinogenesis based on the distribution of somatic mutations. PLoS Comput Biol. 2019; 15(3):e1006881. PMC: 6424461. DOI: 10.1371/journal.pcbi.1006881. View

3.
Sonnenschein C, Soto A . Over a century of cancer research: Inconvenient truths and promising leads. PLoS Biol. 2020; 18(4):e3000670. PMC: 7153880. DOI: 10.1371/journal.pbio.3000670. View

4.
Smyth M, Dunn G, Schreiber R . Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006; 90:1-50. DOI: 10.1016/S0065-2776(06)90001-7. View

5.
Allen B, Hiam K, Burnett C, Venida A, DeBarge R, Tenvooren I . Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020; 26(7):1125-1134. PMC: 7384250. DOI: 10.1038/s41591-020-0892-6. View